EDIT:NASDAQ
Editas Medicine Inc
$2.71
arrow_downward
-9.36%(-0.28) 1D
Jun 5, 11:55:19 AM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EDIT...
Open
$2.97
High
$3.00
Low
$2.69
Mkt. cap
454.71M
Avg. vol.
2.48M
Volume
946.62K
52-wk high
$4.54
52-wk low
$1.66
EPS
-$1.22
Beta
2.16
Shares outstanding
153.46M
No. of employees
87
Open
$2.97
High
$3.00
Low
$2.69
Mkt. cap
454.71M
Avg. vol.
2.48M
Volume
946.62K
52-wk high
$4.54
52-wk low
$1.66
EPS
-$1.22
Beta
2.16
Shares outstanding
153.46M
No. of employees
87
Analyst outlook
Analyst Ratings
Based on 11 analysts giving stock ratings to EDIT in the past 3 months
Buy
Buy
6
Hold
3
Sell
2
12 month forecast
Based on 11 Wall Street analysts offering 12 month price targets for EDIT in the last 3 months.
Highest
Current $2.71
$15.00 (+453.51%)
Average
$6.37 (+135.06%)
Lowest
$4.00 (+47.60%)
News stories
From sources across the web
Yahoo Finance
·
1 day ago
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Stock Titan
·
2 days ago
Commodore reports 16.05M-share position in Editas Medicine (EDIT) under 9.99% cap
The Motley Fool
·
4 days ago
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
Profile
Editas Medicine, Inc., is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado. Wikipedia
About Editas Medicine Inc
AI content may include mistakes. Learn more